Anne Dejean is Director of Research INSERM, Professor at the Institut Pasteur and Head of the Laboratory of Nuclear Organization and Oncogenesis. She graduated from Pierre et Marie Curie University in Paris and earned her PhD in Pierre Tiollais’ lab at the Institut Pasteur in 1983. Member of EMBO and of the French Academy of Sciences, she has received the Hamdan Medicine, Gagna and Van Heck, ARC-Léopold Griffuel, L’Oréal-UNESCO for Women in Science Awards and the Grand Prix INSERM in 2014.
A molecular biologist, Anne Dejean investigates the molecular and cellular mechanisms involved in the development of human cancers. She discovered the role of mutations in retinoic acid receptors in liver cancer and acute promyelocytic leukemia and dissected the molecular mechanisms underlying their role in oncogenesis and treatment sensivity. She identified the retinoic acid receptor beta (RARb) gene at an HBV integration site in a liver cancer, the PML-RARa oncoprotein associated with promyelocytic leukemia and the PML tumor suppressor. She discovered the retinoic acid-reversible disruption of PML Nuclear Bodies in leukemia and the role of sumoylation in the degradation of the PML-RARa oncoprotein and sub-nuclear organization. More recently, her lab has been focusing on the chromatin role of SUMO in regulating cell-specific gene expression programs in patho-physiological processes. Anne Dejean and her collaborators have made important advances in understanding the mechanisms underlying some human tumors and has opened up new perspectives for oncogene-targeted strategies in cancer treatment.